Carisma Therapeutics, Inc. (CARM)

USD 0.46

(-1.62%)

Market Cap (In USD)

19.06 Million

Revenue (In USD)

14.91 Million

Net Income (In USD)

-86.87 Million

Avg. Volume

783.42 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.381-3.16
PE
-
EPS
-
Beta Value
0.0
ISIN
US14216R1014
CUSIP
14216R101
CIK
1485003
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Steven Kelly
Employee Count
-
Website
https://carismatx.com
Ipo Date
2014-02-06
Details
Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response, and technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human diseases. Carisma Therapeutics, Inc. has a strategic collaboration agreement with Moderna Inc. Carisma Therapeutics, Inc. was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was incorporated in 2016 and is based in Philadelphia, Pennsylvania.